SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 is facing downward pressure as traders remain concerned about rising Treasury yields and the geopolitical instability in the Middle East, while community discussion focuses on the impact of potential Federal Reserve rate hikes. While sentiment is notably bearish, investors are actively debating the timing of a potential market rotation and the long-term outlook for AI-related capital expenditure.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as traders grapple with rising long-term Treasury yields and shifting expectations for a potential Federal Reserve rate hike in the face of persistent inflation. The conversation is dominated by debate over whether the Fed will maintain current rates or implement a hike, with many participants expressing skepticism about government intervention efforts to stabilize bond prices.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

The community is discussing Onyx's official completion of the acquisition of Chain technology and intellectual property, with many traders viewing the integration into the Onyx Layer 1 and Wallet as a critical step toward real-world neobank adoption. While some participants are bullish about this foundational shift, others remain skeptical, dismissing the movement as a repeat of previous pump-and-dump cycles.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc - Ordinary Shares - 144A

Nasdaq Inc

Nasdaq Inc. is trending as investors monitor its move to introduce 23-hour trading sessions, which aims to provide near-continuous market access and increase global trading volume. Additionally, the company is drawing attention for recent investments in Kraken parent Payward and the acquisition of the AI-powered due diligence platform Dasseti, reflecting its broader strategy to expand fintech and private market capabilities.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is receiving significant attention as traders debate the impact of industry-wide calls to slow frontier AI development, with many investors dismissing the concerns as a temporary manipulation tactic or irrelevant to the long-term infrastructure buildout. Market sentiment remains divided, characterized by aggressive call-buying from retail participants anticipating a bounce, while others express caution regarding broader macroeconomic headwinds like rising bond yields and inflation data.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending as investors respond to the company's progress in its Phase 3 trial for its lead depression treatment, HLP003, and recent capital-raising efforts. While many traders are optimistic about the upcoming data readout and the sector's potential, some members of the community remain cautious due to concerns regarding potential share dilution.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

The conversation is highly fragmented and dominated by intense political discourse, allegations of corruption, and skepticism regarding economic and military policies. Market-related sentiment is negative, with traders expressing concerns over inflation, rising oil prices, and the broader impact of administration decisions on the economy.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Market volatility is primarily driven by heightened uncertainty surrounding AI development, as industry leaders suggest slowing the pace of innovation due to safety risks. This sentiment has pressured semiconductor and chip stocks, though the market has seen some support from software strength and presidential remarks dismissing the need for new AI restrictions.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

Semiconductor stocks are trending as traders debate the sustainability of the AI-driven infrastructure buildout following concerns raised by industry leaders about the pace of development. While some participants view the pullback as a buying opportunity, others express concern over potential regulatory headwinds, rising interest rates, and broader market correction risks.

Zoracles

Zoracles is experiencing a period of stagnant price action and mixed sentiment, with traders debating whether to hold for potential long-term utility or exit as part of what some characterize as a pump-and-dump cycle. While many investors cite Bitcoin market trends and the need for higher trading volume as primary headwinds, others remain optimistic about the project's long-term potential following recent leadership updates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs

ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.

Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?

Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio

Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio...

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1

ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from its pivotal ALPHA3 study.

Allogene Therapeutics Q1 2026 Earnings Call Transcript

Allogene Therapeutics (ALLO) Projected to Post Quarterly Earnings on Tuesday

Allogene Therapeutics (NASDAQ:ALLO) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-allogene-therapeutics-inc-stock...

Annie Yoshiyama Sells 9,586 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Annie Yoshiyama sold 9,586 shares of the business's stock in a transaction on Tuesday, April 21st. The shares were sold at an average...

Allogene Therapeutics (NASDAQ:ALLO) SVP Annie Yoshiyama Sells 9,586 Shares

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Annie Yoshiyama sold 9,586 shares of the company's stock in a transaction dated Tuesday, April 21st. The stock was sold at an average...

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Allogene Therapeutics Inc

ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’

Equity

Bearish Sentiment

50bps hike

25bps hike

No change

25bps cut

The Federal Reserve's September FOMC meeting concludes Wednesday, September 16, with a rate decision due at 2:00 PM ET, following Tuesday's CPI report that showed inflation still running above the Fed's 2% target. What do you think the Fed decides at this week's FOMC meeting? Vote and explain your reasoning in the comments.

The Fed&#39;s rate decision comes Wednesday at 2PM ET. What do you think happens?

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALLO Allogene Therapeutics Inc

Fundamentals

Latest ALLO News